Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
about
Axitinib for the management of metastatic renal cell carcinomaAxitinib in Metastatic Renal Cell CarcinomaAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Influence of mild and moderate hepatic impairment on axitinib pharmacokineticsEfficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Concise drug review: pazopanib and axitinib.Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerEfficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Population pharmacokinetic analysis of axitinib in healthy volunteers.Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Axitinib in the treatment of metastatic renal cell carcinoma.Pharmacokinetic evaluation of axitinib.Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.Clinical pharmacology of axitinib.Axitinib for the treatment of advanced renal cell carcinoma.Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.Axitinib plasma pharmacokinetics and ethnic differences.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational studyPharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Axitinib: a review in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Pharmacokinetics of single-agent axitinib across multiple solid tumor types.Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.Axitinib: in advanced, treatment-experienced renal cell carcinoma.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner
P2860
Q24613720-7B143063-1405-469D-A921-55EED0658122Q26998017-D01BA05D-02AB-4583-B855-99A43792045AQ34245458-EE7245C3-5B3C-4C71-8710-5CAFBF8853F2Q34538390-3610AEB8-E82D-4E00-9A3F-F29525C39D66Q34661185-55B5A114-97FE-41EC-AC74-6491627EFDF7Q35023711-3E02C9D5-7D0C-44FA-A87F-D7B15EE4308BQ35209594-DECF907B-ADE6-4149-8F8E-BB9D9B45B6B7Q35545820-5BBFEFF1-0AD5-48A9-BED3-25A9C5B43437Q35667342-5BE9204E-B445-41A1-BC3E-7DB58B60054BQ36182836-F76353F4-11C8-4AE0-BB04-0F42D9C127F3Q36387806-A5388FFD-3071-43E2-800A-AAF4E65FC93AQ36467394-E2D7DD63-1DE5-4CD8-847D-4A40091425DDQ36876472-96AEFEEE-17D3-4F2E-89B4-6A7586175C9AQ37387563-7671B8B5-AD36-424A-9156-B846365687D7Q37635202-867ED821-6A8F-4292-9D34-26EFEF63AC41Q37799821-2E736B5B-F28D-4922-83FD-0E5A8F696A47Q37951599-FED50B96-64BE-4440-AB9D-2CFA15051310Q37976135-87C1FC0F-F19B-47C7-9C06-0B065C179CA8Q38015387-29A7C1ED-C4E0-4ACA-A448-78CCA5E87DCCQ38107175-CA0D2685-439D-4B00-8C58-DF1A1E85C508Q38170397-4BA19DA8-0B07-400C-80E5-F5596A218EC8Q38196939-96445BE8-7E59-49C6-A9FB-FC39E80F2C96Q38348548-9D812050-D26C-4766-9360-C2AB3C16FF12Q38514440-7D8F8865-0BFB-419E-A9D4-F752499E8438Q38531928-CE915AD7-9C92-46EA-AF03-BA2F1406A8AAQ38552109-47FF6358-EFC0-4614-863A-8CC66AEC5AA7Q38612808-5B6EB418-8139-45FD-B758-C5B06708D97AQ38657787-E23DF999-6F1B-4F4E-8BC2-ECC297F6CFBEQ39031326-9DE3A471-2E56-4321-B434-53D8B0A79CB8Q39560865-B8A1004D-4CA3-4A04-8B33-E565A9164C8FQ42364404-5EFEE937-8CCE-44FD-8B34-F22AEBE62D71Q44982199-9DFB61B2-363F-4F1F-9AE7-3CE78B7871A3Q45916609-F8D5B2CD-8B74-45D9-8276-7C9BEE2882C0Q50091855-27E85EFD-E8E4-4F63-ABE9-EA243309FCCDQ51356317-4519932B-7CC1-415D-962D-E1A42DB9B830Q54469002-F00BFD8F-C242-4C21-9D54-EFDCCB5398B0Q57498748-2B00F80B-32EF-4262-947F-95499226A1AB
P2860
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@ast
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@en
Effect of rifampin on the pharmacokinetics of Axitinib
@nl
type
label
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@ast
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@en
Effect of rifampin on the pharmacokinetics of Axitinib
@nl
prefLabel
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@ast
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@en
Effect of rifampin on the pharmacokinetics of Axitinib
@nl
P2093
P2860
P1476
Effect of rifampin on the phar ...... d Caucasian healthy volunteers
@en
P2093
K J Klamerus
M Tortorici
U Kuruganti
Y K Pithavala
P2860
P2888
P304
P356
10.1007/S00280-009-1065-Y
P577
2009-07-15T00:00:00Z
P5875
P6179
1004421187